Gender effect on cardiac involvement in myotonic dystrophy type 1.
CTG expansion
cardiac abnormalities
gender
myotonic dystrophy
sudden death
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
12
10
2020
revised:
19
11
2020
accepted:
26
11
2020
pubmed:
8
12
2020
medline:
13
8
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Cardiac involvement is observed in about 80% of subjects with myotonic dystrophy type 1 (DM1) and is mainly characterized by cardiac conduction and/or rhythm abnormalities (CCRAs), possibly leading to sudden cardiac death (SCD). Our objective was to investigate whether the gender difference may influence the cardiac involvement and SCD in DM1. We analyzed prevalence and incidence of cardiological abnormalities in males versus females in 151 consecutive DM1 patients over a 35-year follow-up period. Fifty-five patients, 35 males (62.5%) and 20 females (42.5%), developed some type of CCRA during the follow-up period (mean 7.82 ± 6.21 years). CCRA overall, and specifically cardiac conduction abnormalities (CCAs), were significantly more frequent in males than in females (p = 0.043 and p = 0.031, respectively). CCRAs progressed in 16 males (45.7%) and six females (30%). Twenty-four patients, 14 males (25.0%) and 10 females (21.3%), died during the follow-up. Nine of them, six males (10.7%) and three females (6.4%), had SCD. After correction for Muscular Impairment Rating Scale progression, cytosine thymine-guanine expansion, and follow-up duration, a higher prevalence of CCAs was independently associated with male gender (p = 0.039), but independent association with gender was not detected for CCRAs overall, cardiac rhythm abnormalities, and SCD prevalence, even if prevalence was higher in males than females. The overall risk of occurrence of CCAs in DM1 is significantly higher in males than females regardless of genetic background and disease severity and progression. Moreover, the data also suggest a similar impact for male gender for CCRAs overall, CCAs, and SCD even if not statistically significant.
Sections du résumé
BACKGROUND AND PURPOSE
Cardiac involvement is observed in about 80% of subjects with myotonic dystrophy type 1 (DM1) and is mainly characterized by cardiac conduction and/or rhythm abnormalities (CCRAs), possibly leading to sudden cardiac death (SCD). Our objective was to investigate whether the gender difference may influence the cardiac involvement and SCD in DM1.
METHODS
We analyzed prevalence and incidence of cardiological abnormalities in males versus females in 151 consecutive DM1 patients over a 35-year follow-up period.
RESULTS
Fifty-five patients, 35 males (62.5%) and 20 females (42.5%), developed some type of CCRA during the follow-up period (mean 7.82 ± 6.21 years). CCRA overall, and specifically cardiac conduction abnormalities (CCAs), were significantly more frequent in males than in females (p = 0.043 and p = 0.031, respectively). CCRAs progressed in 16 males (45.7%) and six females (30%). Twenty-four patients, 14 males (25.0%) and 10 females (21.3%), died during the follow-up. Nine of them, six males (10.7%) and three females (6.4%), had SCD. After correction for Muscular Impairment Rating Scale progression, cytosine thymine-guanine expansion, and follow-up duration, a higher prevalence of CCAs was independently associated with male gender (p = 0.039), but independent association with gender was not detected for CCRAs overall, cardiac rhythm abnormalities, and SCD prevalence, even if prevalence was higher in males than females.
CONCLUSIONS
The overall risk of occurrence of CCAs in DM1 is significantly higher in males than females regardless of genetic background and disease severity and progression. Moreover, the data also suggest a similar impact for male gender for CCRAs overall, CCAs, and SCD even if not statistically significant.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1366-1374Informations de copyright
© 2020 European Academy of Neurology.
Références
Ashizawa T, Gagnon C, Groh WJ, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract. 2018;8:507-520. https://doi.org/10.1212/CPJ.0000000000000531
Wahbi K, Furling D. Cardiovascular manifestations of myotonic dystrophy. Trends Cardiovasc Med. 2019;30:232-238. https://doi.org/10.1016/j.tcm.2019.06.001
Rossi S, Della Marca G, Ricci M, et al. Prevalence and predictor factors of respiratory impairment in a large cohort of patients with Myotonic Dystrophy type 1 (DM1): a retrospective, cross sectional study. J Neurol Sci. 2019;399:118-124. https://doi.org/10.1016/j.jns.2019.02.012
Spaziani M, Semeraro A, Bucci E, et al. Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study. J Endocrinol Invest. 2019;43:663-675. https://doi.org/10.1007/s40618-019-01156-w
Choi SH, Yang HK, Hwang J-M, Park KS. Ocular findings of myotonic dystrophy type 1 in the Korean population. Graefes Arch Clin Exp Ophthalmol. 2016;254:1189-1193. https://doi.org/10.1007/s00417-016-3266-5
Laberge L, Gallais B, Auclair J, et al. Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1. J Neurol. 2020;267:461-468. https://doi.org/10.1007/s00415-019-09592-7
Okkersen K, Monckton DG, Le N, et al. Brain imaging in myotonic dystrophy type 1: a systematic review. Neurology. 2017;89:960-969. https://doi.org/10.1212/WNL.0000000000004300
Tomé S, Gourdon G. DM1 phenotype variability and triplet repeat instability: challenges in the development of new therapies. Int J Mol Sci. 2020;21:457. https://doi.org/10.3390/ijms21020457
Cumming SA, Jimenez-Moreno C, Okkersen K, et al. Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology. 2019;93:e995-e1009. https://doi.org/10.1212/WNL.0000000000008056
Vanacore N, Rastelli E, Antonini G, et al. An age-standardized prevalence estimate and a sex and age distribution of myotonic dystrophy types 1 and 2 in the Rome Province, Italy. Neuroepidemiology. 2016;46:191-197. https://doi.org/10.1159/000444018
Theadom A, Rodrigues M, Poke G, et al. A nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology. 2019;52:128-135. https://doi.org/10.1159/000494115
Bucci E, Testa M, Licchelli L, et al. A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre. J Neurol. 2018;265:885-895. https://doi.org/10.1007/s00415-018-8773-3
Wahbi K, Babuty D, Probst V, et al. Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur Heart J. 2017;38:751-758. https://doi.org/10.1093/eurheartj/ehw569
Chong-Nguyen C, Wahbi K, Algalarrondo V, et al. Association between mutation size and cardiac involvement in myotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc Genet. 2017;10:e001526. https://doi.org/10.1161/CIRCGENETICS.116.001526
Chaudhry S-P, Frishman WH. Myotonic dystrophies and the heart. Cardiol Rev. 2012;20:1-3. https://doi.org/10.1097/CRD.0b013e31821950f9
Ouyang L, Wang Y, Valdez R, et al. Gender difference in clinical conditions among hospitalized adults with myotonic dystrophy. Muscle Nerve. 2019;59:348-353. https://doi.org/10.1002/mus.26402
Teveroni E, Pellegrino M, Sacconi S, et al. Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. J Clin Invest. 2017;127:1531-1545. https://doi.org/10.1172/JCI89401
Dogan C, De Antonio M, Hamroun D, et al. Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS One. 2016;11:e0148264. https://doi.org/10.1371/journal.pone.0148264
Botta A, Bonifazi E, Vallo L, et al. Italian guidelines for molecular analysis in myotonic dystrophies. Acta Myol. 2006;25:23-33.
Mathieu J, Boivin H, Meunier D, et al. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001;56:336-340. https://doi.org/10.1212/wnl.56.3.336
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138:e272-e391. https://doi.org/10.1161/CIR.0000000000000549
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8:1308-1339. https://doi.org/10.1016/j.hrthm.2011.05.020
Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688-2697. https://doi.org/10.1056/NEJMoa062800
Petri H, Vissing J, Witting N, et al. Cardiac manifestations of myotonic dystrophy type 1. Int J Cardiol. 2012;160:82-88. https://doi.org/10.1016/j.ijcard.2011.08.037
Nikhanj A, Sivakumaran S, Miskew-Nichols B, et al. Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series. Eur Heart J Case Rep. 2019;3:ytz095. https://doi.org/10.1093/ehjcr/ytz095
Nazarian S, Wagner KR, Caffo BS, Tomaselli GF. Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol. 2011;34:171-176. https://doi.org/10.1111/j.1540-8159.2010.02905.x
Brembilla-Perrot B, Schwartz J, Huttin O, et al. Atrial flutter or fibrillation is the most frequent and life-threatening arrhythmia in myotonic dystrophy. Pacing Clin Electrophysiol. 2014;37:329-335. https://doi.org/10.1111/pace.12260
Cudia P, Bernasconi P, Chiodelli R, et al. Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. J Neurol Neurosurg Psychiatry. 2009;80:790-793. https://doi.org/10.1136/jnnp.2008.162594
Russo V, Rago A, Ciardiello C, et al. The role of the atrial electromechanical delay in predicting atrial fibrillation in myotonic dystrophy type 1 patients. J Cardiovasc Electrophysiol. 2016;27:65-72. https://doi.org/10.1111/jce.12821
Stöllberger C, Steger C, Gabriel P, Finsterer J. Implantable loop recorders in myotonic dystrophy 1. Int J Cardiol. 2011;152:249-251. https://doi.org/10.1016/j.ijcard.2011.07.085
Park KM, Shin KJ, Kim SE, et al. Prolonged corrected QT interval in patients with myotonic dystrophy type 1. J Clin Neurol. 2013;9:186-191. https://doi.org/10.3988/jcn.2013.9.3.186
Vink AS, Clur S-AB, Wilde AAM, Blom NA. Effect of age and gender on the QTc-interval in healthy individuals and patients with long-QT syndrome. Trends Cardiovasc Med. 2018;28:64-75. https://doi.org/10.1016/j.tcm.2017.07.012
Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex and age differences in ventricular repolarization in humans. Am Heart J. 2014;168:749-756. https://doi.org/10.1016/j.ahj.2014.07.010
Groh WJ, Groh MR, Shen C, et al. Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve. 2011;43:648-651. https://doi.org/10.1002/mus.21934
Antonini G, Giubilei F, Mammarella A, et al. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology. 2000;55:1207-1209. https://doi.org/10.1212/wnl.55.8.1207
Gladman JT, Mandal M, Srinivasan V, Mahadevan MS. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1). PLoS One. 2013;8:e72907. https://doi.org/10.1371/journal.pone.0072907
Minghetti L, Greco A, Zanardo V, Suppiej A. Early-life sex-dependent vulnerability to oxidative stress: the natural twining model. J Matern Fetal Neonatal Med. 2013;26:259-262. https://doi.org/10.3109/14767058.2012.733751
Gagnon C, Chouinard MC, Laberge L, et al. Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord. 2010;20:847-851. https://doi.org/10.1016/j.nmd.2010.08.006
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Rev Esp Cardiol (Engl Ed). 2016;69:176. https://doi.org/10.1016/j.rec.2016.01.001
Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307:1292-1301. https://doi.org/10.1001/jama.2012.346
Hermans MCE, Pinto YM, Merkies ISJ, et al. Hereditary muscular dystrophies and the heart. Neuromuscul Disord. 2010;20:479-492. https://doi.org/10.1016/j.nmd.2010.04.008